Neurocrine Biosciences | NBIX - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
AbbVie USD 64.53B 5.59B 2026-03
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
ALKERMES USD 1.48B 7.23M 2026-06
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Amgen USD 51.86B 27M 2026-06
Biogen USD 7.29B 1B 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Cytokinetics USD 248.2M 993K 2026-06
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 20.86B 1.27B 2026-03
Halozyme Therapeutics USD 1.94B 1.79M 2026-06
Incyte USD 28.42M 994K 2026-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Pfizer USD 60.5B 70M 2026-06
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Repligen USD 551.05M 4.46M 2026-06
Rigel Pharmaceuticals USD 0 0 2024-09
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Teva Pharmaceutical Industries USD 12.09B 1.92B 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12